| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G |
| P698 | PubMed publication ID | 10639195 |
| P2093 | author name string | Ni Z | |
| Tweardy DJ | |||
| Dyer K | |||
| Gao AC | |||
| Lou W | |||
| P2860 | cites work | Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells | Q24317507 |
| Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway | Q24531184 | ||
| Transcriptional responses to polypeptide ligands: the JAK-STAT pathway | Q29620287 | ||
| Expression of homeobox gene-GBX2 in human prostatic cancer cells | Q41147718 | ||
| Interleukin-6: a candidate mediator of human prostate cancer morbidity | Q41362792 | ||
| Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells | Q41645085 | ||
| P433 | issue | 3 | |
| P921 | main subject | prostate cancer | Q181257 |
| cell growth | Q189159 | ||
| P304 | page(s) | 239-242 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | The Prostate | Q7758608 |
| P1476 | title | Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . | |
| P478 | volume | 42 |
| Q38725604 | A novel anti-viral role for STAT3 in IFN-α signalling responses |
| Q42855019 | Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway |
| Q40888865 | An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal |
| Q47272097 | Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer |
| Q34714834 | Andrographolide, an Herbal Medicine, Inhibits Interleukin-6 Expression and Suppresses Prostate Cancer Cell Growth |
| Q38695963 | Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway |
| Q37638228 | Beyond structure, to survival: activation of Stat3 by cadherin engagement |
| Q35289346 | Bigelovin inhibits STAT3 signaling by inactivating JAK2 and induces apoptosis in human cancer cells |
| Q28659942 | BioTCM-SE: a semantic search engine for the information retrieval of modern biology and traditional Chinese medicine |
| Q37690567 | Breast and prostate cancer: more similar than different. |
| Q38688878 | Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells |
| Q57114753 | Carcinogenesis in prostate cancer: The role of long non-coding RNAs |
| Q36196682 | Castration-resistant prostate cancer: potential targets and therapies. |
| Q81156925 | Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer |
| Q34917061 | Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse |
| Q31864260 | Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells |
| Q34633681 | Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice. |
| Q64121016 | DNA methylation among firefighters |
| Q34332447 | Diallyl Trisulfide Inhibits Activation of Signal Transducer and Activator of Transcription 3 in Prostate Cancer Cells in Culture and In vivo |
| Q36732591 | Differential effects of leptin on the invasive potential of androgen-dependent and -independent prostate carcinoma cells |
| Q38112122 | Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer |
| Q61818124 | Downregulation of Pro-Inflammatory and Pro-Angiogenic Pathways in Prostate Cancer Cells by a Polyphenol-Rich Extract from Olive Mill Wastewater |
| Q37424118 | Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells |
| Q38801346 | Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment |
| Q40114720 | Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. |
| Q56962789 | Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma |
| Q39635813 | Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation |
| Q28304032 | Extracellular Hsp90 mediates an NF-κB dependent inflammatory stromal program: implications for the prostate tumor microenvironment |
| Q95424193 | Factors modifying transcriptional regulation of signaling genes have putative role in tumor development and progression in humans |
| Q73078899 | Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation |
| Q40422307 | IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells |
| Q52006477 | IL-6 is constitutively expressed during lung morphogenesis and enhances fetal lung explant branching |
| Q24794588 | IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells |
| Q37968599 | IL-6/IL-6R as a potential key signaling pathway in prostate cancer development |
| Q53784890 | Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice |
| Q24685955 | Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma |
| Q36908883 | Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma |
| Q34094656 | Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells |
| Q39549298 | Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion |
| Q34389853 | Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells |
| Q53277140 | Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin‐6 in the androgen‐independent human prostate cancer PC3 model |
| Q30584010 | Integrative pathway analysis of genome-wide association studies and gene expression data in prostate cancer |
| Q34440657 | Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes |
| Q43589705 | Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells |
| Q42613190 | Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. |
| Q38995864 | Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). |
| Q35747214 | Interleukin-6 is an autocrine growth factor in human prostate cancer. |
| Q34158970 | Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth |
| Q39819739 | Interleukin-6 regulates androgen synthesis in prostate cancer cells |
| Q24746259 | Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. |
| Q33724843 | Interleukins, laminin and epstein - barr virus latent membrane protein 1 (EBV LMP1) Promote metastatic phenotype in nasopharyngeal carcinoma |
| Q38369000 | Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer |
| Q35635353 | JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis |
| Q96431705 | KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1 |
| Q33813952 | Knockout of the Nogo-B Gene Attenuates Tumor Growth and Metastasis in Hepatocellular Carcinoma |
| Q36879620 | LNCaP prostate cancer cells with autocrine interleukin‐6 expression are resistant to IL‐6‐induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling |
| Q38341864 | Leading causes of castration-resistant prostate cancer |
| Q53636330 | Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer |
| Q28217019 | Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells |
| Q98224203 | LncRNA IGFBP4-1 promotes tumor development by activating Janus kinase-signal transducer and activator of transcription pathway in bladder urothelial carcinoma |
| Q39581495 | Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop |
| Q43181974 | MicroRNA-181b regulates endotoxin tolerance by targeting IL-6 in macrophage RAW264.7 cells |
| Q46255425 | MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway |
| Q24317585 | Modulation of androgen receptor transactivation by FoxH1. A newly identified androgen receptor corepressor |
| Q37630578 | Molecular mechanisms of castration-resistant prostate cancer progression |
| Q28741023 | Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling |
| Q28477663 | Necdin, a Negative Growth Regulator, Is a Novel STAT3 Target Gene Down-Regulated in Human Cancer |
| Q43787028 | Neither Fibroblast Growth Factor-1 Nor Fibroblast Growth Factor-2 Is an Androgen Receptor Coactivator in Androgen-Resistant Prostate Cancer |
| Q38875469 | Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition |
| Q74582412 | Normal and SV40 transfected human peritoneal mesothelial cells produce IL-6 and IL-8: implication for gynaecological disease |
| Q36216910 | Oral low-dose dexamethasone for androgen-independent prostate cancer patients |
| Q51548625 | Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor |
| Q64375227 | Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo |
| Q44253336 | Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study |
| Q40240427 | Phaeosphaeride A, an inhibitor of STAT3-dependent signaling isolated from an endophytic fungus |
| Q34363785 | Pharmacologic Inhibition of Jak2–Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer |
| Q38482656 | Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells |
| Q38693670 | Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer. |
| Q44441026 | Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin‐6 |
| Q38027835 | Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects |
| Q36923290 | PrLZ Protects Prostate Cancer Cells from Apoptosis Induced by Androgen Deprivation via the Activation of Stat3/Bcl-2 Pathway |
| Q42014039 | Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. |
| Q34504232 | Prostate adenocarcinoma: cellular and molecular abnormalities |
| Q35141115 | Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine? |
| Q28278555 | Prostate cancer and the met hepatocyte growth factor receptor |
| Q34155571 | Protein kinases as therapeutic targets |
| Q38386536 | RhoGDIα suppresses growth and survival of prostate cancer cells |
| Q38776978 | Role of STAT3 pathway in genitourinary tumors. |
| Q35911116 | STAT proteins as novel targets for cancer drug discovery |
| Q34293579 | STAT proteins: novel molecular targets for cancer drug discovery |
| Q36053053 | STAT3 and transactivation of steroid hormone receptors |
| Q37029162 | STAT3 as a target for inducing apoptosis in solid and hematological tumors |
| Q38850627 | STAT3 regulated ARF expression suppresses prostate cancer metastasis |
| Q54942168 | STAT3-Mediated Transcriptional Regulation of Osteopontin in STAT3 Loss-of-Function Related Hyper IgE Syndrome. |
| Q37423674 | SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer |
| Q38795784 | Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer |
| Q64119071 | Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication |
| Q42516108 | Signal transducer and activator of transcription-3 expression and activation is dysregulated in actinic cheilitis. |
| Q34722254 | Signaling inhibitors in the treatment of prostate cancer |
| Q24795887 | Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells |
| Q99710913 | Stat2 stability regulation: an intersection between immunity and carcinogenesis |
| Q53390466 | Stat3 activation in prostatic carcinomas |
| Q74447273 | Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice |
| Q24792987 | Stat3 enhances transactivation of steroid hormone receptors |
| Q37848782 | Steps in prostate cancer progression that lead to bone metastasis |
| Q43084872 | Stromal TGF-β signaling induces AR activation in prostate cancer |
| Q33785752 | Sulforaphane inhibits constitutive and interleukin-6-induced activation of signal transducer and activator of transcription 3 in prostate cancer cells |
| Q33762943 | Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. |
| Q36232040 | TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells |
| Q41447690 | Targeted blockade of TGF-β and IL-6/JAK2/STAT3 pathways inhibits lung cancer growth promoted by bone marrow-derived myofibroblasts |
| Q33613105 | The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors |
| Q36836686 | The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? |
| Q38199934 | The Role of STAT3 in Non-Small Cell Lung Cancer |
| Q29614601 | The STATs of cancer--new molecular targets come of age |
| Q79314186 | The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1 |
| Q47261122 | The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells. |
| Q38614374 | The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment. |
| Q38796729 | The role of microRNA-26a in human cancer progression and clinical application |
| Q36361936 | Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol |
| Q33745272 | Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. |
| Q44508741 | Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways |
| Q33844812 | Ultrasensitive Label-Free Sensing of IL-6 Based on PASE Functionalized Carbon Nanotube Micro-Arrays with RNA-Aptamers as Molecular Recognition Elements. |
| Q34253370 | Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells |
| Q39965149 | Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines |
| Q37364129 | aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. |
| Q38149939 | gp130: a promising drug target for cancer therapy |
Search more.